AstraZeneca PLC (AZN.L)
AZN.L on London Stock Exchange
4,955.50GBp
19 Apr 2018
4,955.50GBp
19 Apr 2018
Change (% chg)
-9.00 (-0.18%)
-9.00 (-0.18%)
Prev Close
4,964.50
4,964.50
Open
4,976.00
4,976.00
Day's High
5,015.00
5,015.00
Day's Low
4,937.50
4,937.50
Volume
1,560,380
1,560,380
Avg. Vol
2,112,866
2,112,866
52-wk High
5,585.07
5,585.07
52-wk Low
4,260.00
4,260.00
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 0.88 | December | 20 Apr 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 10 | 9 | 9 | 9 |
| (2) OUTPERFORM | 12 | 12 | 13 | 12 |
| (3) HOLD | 5 | 7 | 7 | 7 |
| (4) UNDERPERFORM | 3 | 3 | 4 | 5 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.03 | 2.13 | 2.18 | 2.24 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 8 | 5,494.64 | 5,690.00 | 5,261.00 | 5,586.97 |
| Quarter Ending Sep-18 | 8 | 5,618.15 | 5,706.00 | 5,490.00 | 5,646.75 |
| Year Ending Dec-18 | 29 | 22,568.50 | 23,169.00 | 20,818.00 | 22,487.00 |
| Year Ending Dec-19 | 31 | 23,913.40 | 26,486.00 | 21,788.00 | 24,254.20 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 7 | 0.88 | 1.00 | 0.74 | 0.92 |
| Quarter Ending Sep-18 | 7 | 0.84 | 1.03 | 0.74 | 1.12 |
| Year Ending Dec-18 | 31 | 3.39 | 4.16 | 2.14 | 3.93 |
| Year Ending Dec-19 | 33 | 3.97 | 4.94 | 3.16 | 4.53 |
| LT Growth Rate (%) | 6 | 5.21 | 12.10 | -0.40 | 5.26 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Dec-17 | 5,473.40 | 5,777.00 | 303.60 | 5.55 |
| Quarter Ending Sep-17 | 5,972.46 | 6,232.00 | 259.54 | 4.35 |
| Quarter Ending Jun-17 | 5,043.25 | 5,051.00 | 7.75 | 0.15 |
| Quarter Ending Mar-17 | 5,408.17 | 5,405.00 | 3.17 | 0.06 |
| Quarter Ending Dec-16 | 5,568.38 | 5,585.00 | 16.62 | 0.30 |
| Earnings (per share) | ||||
| Quarter Ending Dec-17 | 0.84 | 1.30 | 0.46 | 54.91 |
| Quarter Ending Sep-17 | 1.07 | 1.12 | 0.05 | 4.22 |
| Quarter Ending Jun-17 | 0.80 | 0.87 | 0.07 | 8.40 |
| Quarter Ending Mar-17 | 0.82 | 0.99 | 0.17 | 20.86 |
| Quarter Ending Dec-16 | 1.13 | 1.21 | 0.08 | 6.87 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 5,494.64 | 5,505.98 | 5,447.43 | 5,407.29 | 5,586.97 |
| Quarter Ending Sep-18 | 5,618.15 | 5,607.38 | 5,552.77 | 5,532.11 | 5,646.75 |
| Year Ending Dec-18 | 22,568.50 | 22,574.90 | 22,458.20 | 22,318.60 | 22,487.00 |
| Year Ending Dec-19 | 23,913.40 | 23,916.20 | 23,852.70 | 23,799.50 | 24,254.20 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 0.88 | 0.88 | 0.86 | 0.84 | 0.92 |
| Quarter Ending Sep-18 | 0.84 | 0.87 | 0.86 | 0.83 | 1.12 |
| Year Ending Dec-18 | 3.39 | 3.40 | 3.42 | 3.47 | 3.93 |
| Year Ending Dec-19 | 3.97 | 3.96 | 3.94 | 3.98 | 4.53 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 0 | 2 | 1 | 2 |
| Quarter Ending Sep-18 | 1 | 1 | 2 | 1 |
| Year Ending Dec-18 | 1 | 2 | 4 | 4 |
| Year Ending Dec-19 | 1 | 2 | 5 | 3 |
| Earnings | ||||
| Quarter Ending Jun-18 | 1 | 1 | 2 | 1 |
| Quarter Ending Sep-18 | 0 | 2 | 1 | 2 |
| Year Ending Dec-18 | 1 | 4 | 3 | 5 |
| Year Ending Dec-19 | 2 | 3 | 6 | 3 |
Earnings vs. 
Estimates- UPDATE 1-UK Stocks-Factors to watch on April 19
- UK Stocks-Factors to watch on April 19
- UPDATE 1-AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug
- AstraZeneca wins U.S. FDA approval for 1st-line use of lung cancer drug
- BRIEF-Roche Expands Indication For Cobas EGFR Mutation Test V2 As Companion Diagnostic With Tagrisso
- Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update?
- What does AstraZeneca plc's deal with Pfizer mean for shareholders?
- 3 stocks to help you retire early
- Is it time to take profits on GlaxoSmithKline plc and AstraZeneca plc?
- These FTSE 100 stars have exploded in Q3! And they're not finished yet
- Why now is the perfect time to buy these 3 super income stocks